HBK Investments’s Mersana Therapeutics MRSN Stock Holding History

HBK Investments’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-800	Closed	-$279K	–	1084
2017 Q2	$279K	Buy	+800	New	+$277K	﹤0.01%	825

Other funds holding MRSN

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments's MRSN Position: Q3 2017 in Review

HBK Investments sold out of Mersana Therapeutics (MRSN) in Q3 2017, closing a stake of 800 shares — an estimated $279K sold.

HBK Investments first reported a position in MRSN in Q2 2017 and held it in 1 quarter. The position peaked at $279K in Q2 2017. 42 funds tracked by Wall St. Rank hold MRSN as of Q3 2017.

HBK Investments reported no remaining Mersana Therapeutics position as of Q3 2017 after selling out during the quarter.
HBK Investments sold 800 Mersana Therapeutics shares in Q3 2017, an estimated $279K.
HBK Investments first reported a position in Mersana Therapeutics in Q2 2017 and held it in 1 quarter.
HBK Investments's Mersana Therapeutics position peaked at $279K in Q2 2017.
42 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2017.

Based on HBK Investments's 13F filing for Q3 2017, filed 14 Nov 2017.